Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...

Forbes contributors publish independent expert analyses and insights. Randy Bean is a noted Senior Advisor, Author, Speaker, Founder, & CEO. Visa (NYSE: V), a world leader in digital payments, is ...

Today, tech media The Recursive announces a new leadership structure to guide its next chapter. Teodor Antonio Georgiev has been appointed Chief Executive Officer, joined by Etien Yovchev and Dilyana ...

Boltz-2 is an open-source biomolecular model achieving near-FEP accuracy with 1000x faster predictions for structure and binding affinity. MIT and Recursion have released Boltz-2, the first ...

Hello there! 👋 I'm Luca, a BI Developer with a passion for all things data, Proficient in Python, SQL and Power BI ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...

Structure content for AI search so it’s easy for LLMs to cite. Use clarity, formatting, and hierarchy to improve your visibility in AI results. In the SEO world, when we talk about how to structure ...

Recursion, a clinical-stage TechBio company, is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, at the 2025 Digestive Disease Week (DDW) meeting on May 4, 2025, in San ...

We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against ...